Japanese  
  Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Crizotinib Reduces Tumor Size in… >
Crizotinib Reduces Tumor Size in Patients with ALK Positive Lung Cancer

Published: September 7, 2012.
By American Society for Radiation Oncology
http://www.astro.org

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

ALK gene rearrangements are found in around 5 percent of lung cancer tumors and are more common in people with lung cancer who never smoked. Crizotinib is an oral drug that was found to inhibit the effects of the ALK gene and to stop or reverse tumor growth.

In this phase II trial, researchers followed 901 patients for safety and 261 patients for tumor response; all of the patients had at least one prior chemotherapy treatment for their lung cancer. The overall response rate to crizotinib treatment was 60 percent and the median progression free survival (PFS) was eight months, confirming prior findings that crizotinib shrinks ALK-positive lung cancers and demonstrates a high PFS rate.

"This trial demonstrates that we have a good opportunity to shrink cancers and improve symptoms for patients with this subtype of lung cancer," said Gregory Riely, MD, PhD, lead author of the study and a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York who specializes in treating lung cancer. "This confirms the results of prior studies and further shows that crizotinib can reduce the effects of symptoms, thereby improving the quality of life for thousands of patients who are diagnosed with this late-stage lung cancer. This study confirms that crizotinib is the standard of care for patients with ALK positive lung cancer."




Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
This is form to send feedback to the editors. Tell us what you think about this article. All comments are not published. If you are looking for a response to a question please use our another feedback page.
Related »

Cancer 
10/28/10 
People with Specific Kind of Lung Cancer Respond to New Targeted Treatment
By University of Colorado Denver
AURORA, Colo. (Oct. 28, 2010) - A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are …
Cancer 
3/7/11 
Clinical Observation Leads to Lung Cancer Discovery
By University of Colorado Denver
AURORA, Colo. (March 7, 2011) - A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly …
Cancer 
6/4/11 
Benefit of Targeted Lung Cancer Therapy Confirmed
By University of Colorado Denver
AURORA, Colo. (June 3, 2011) – A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take …
Patients 
7/5/11 
ALK Rearrangement Found in Nearly 10% of Patients in Lung Cancer Mutation Consortium
By International Association for the Study of Lung Cancer
ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might …
Molecular 
2/3/12 
New Research Confirms Need for Lung Cancer Testing
By University of Colorado Denver
Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official …
More » 
 
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.